Pharmaceuticals

CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency

SHANGHAI, Sept. 23, 2019 /PRNewswire/ -- CARsgen Therapeutics Inc., a clinical-stage biopharmaceutical company today announced the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) eligibility to its investigational CAR-T cell therapy fully human anti-BCMA (B Cell Maturation ...

2019-09-23 18:00 5705

CPhI recruiting freelance pharmaceutical authors contributing to the global industry professionals

SHANGHAI, Sept. 23, 2019 /PRNewswire/ -- CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry globally. As the initiator of an Internet platform for knowledge sharing in the pharmaceutical field, CPhI.CN aims to create hot industry content to achieve effective commu...

2019-09-23 17:56 1749

New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care

Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455,Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: 4062; 4934. * N...

2019-09-23 14:00 2714

2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors

SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced results from the microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) solid tumor cohort in the GEMSTONE-101 Phase Ib study of the Company's investigation...

2019-09-22 14:22 1615

2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab

SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced preliminary results from the Phase Ia trial of the Company's anti-CTLA-4 antibody in an oral presentation at the 22nd Annual Meeting of the Chinese Society of Clinical Onco...

2019-09-22 13:39 1796

2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors

SUZHOU, China, Sept. 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today released the preliminary data from the Phase I bridging study of the Company's investigational anti-PD-1 monoclonal antibody CS1003 for the first time, in an oral presentation at the...

2019-09-21 00:26 1865

CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

Not intended for US, Canada and UK-based media  * Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib[1] * Decision by the European Commission anticipated in fourth quarter of 2019...

2019-09-20 20:34 2364

Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO

SUZHOU, China, Sept. 20, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, metabolic and other major diseases, announced today that the data for tw...

2019-09-20 14:30 8684

2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%

SUZHOU, China, Sept. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced trial data from the esophageal squamous cell carcinoma (ESCC) cohort of a Phase Ib clinical trial of the Company's investigational anti-PD-L1 antibody CS1001 in an oral pre...

2019-09-19 23:48 1971

Advanced Aesthetic Technologies and China National Biotec Group Announce Strategic Cooperation

BROOKLINE, Massachusetts, Sept. 19, 2019 /PRNewswire/ -- Advanced Aesthetic Technologies, Inc. (AAT), a leader in aesthetic gel implant technology, and China National Biotec Group (CNBG), a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM) today announced the execution of ...

2019-09-19 23:12 3155

Chipscreen Biosciences's Oringinal New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted

SHENZHEN, China, Sept. 19, 2019 /PRNewswire/ -- The new drug application (NDA) of Chiglitazar (Bilessglu®), an innovative new chemical entity (Category 1 c hemical drug) for type 2 diabetes discovered and developed by Shenzhen Chipscreen Biosciences (Stock Symbol: 688321.SH), has been accepted by ...

2019-09-19 23:02 2195

Tresiba® Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes

BARCELONA, Spain, Sept. 19, 2019 /PRNewswire/ -- According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in a...

2019-09-19 18:01 2111

Innovent Provides Update on the Results of IBI305 for the First-line Treatment of Advanced Non-squamous Cell Lung Cancer by Oral Presentation at CSCO

SUZHOU, China, Sept. 19, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, metabolic and other major diseases, announced today that the results of ...

2019-09-19 16:36 8228

China Biologic Announces Receipt of Preliminary Non-Binding "Going Private" Proposal

BEIJING, Sept. 18, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that its board of directors (the "Board") has received a preliminary non-bin...

2019-09-19 04:01 11738

Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection

PLYMOUTH MEETING, Pennsylvania, Sept. 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that the company and its collaborator The Wistar Institute have received a$4.6 million National Institutes of Health (NIH) grant in support of innovative research to tackle a...

2019-09-17 21:00 2758

AMPAC Fine Chemicals and SK biotek Become New US Corporation Focused on Expanded Support to the World's Pharmaceutical Industry

SACRAMENTO, California, Sept. 17, 2019 /PRNewswire/ -- SK Holdings, the holding company ofSouth Korea's SK Group, has established SK pharmteco, a U.S.-based Contract Manufacturing Organization (CMO) supporting Pharmaceutical Customers worldwide. This move combines SK biotek in Korea, SK biotek in...

2019-09-17 04:35 2807

Ping An Good Doctor Joins Forces with the People's Government of Guangxi Zhuang Autonomous Region to Build Internet Healthcare Platform Opening up a Window for ASEAN to Seek Healthcare Services

SHANGHAI, Sept. 16, 2019 /PRNewswire/ -- The world's leading online healthcare ecosystem platform, Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor"; stock code: 01833.HK) entered into a strategic cooperation agreement (the "Agreement") with China Council for the Promotion ...

2019-09-16 21:04 6006

Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins Using Mass Spectrometry

STOCKHOLM, Sept. 16, 2019 /PRNewswire/ -- Atlas Antibodies AB, a leading supplier of advanced research reagents, announced today the introduction of pre-quantified QPrEST™ Protein Standards for absolute quantification of proteins in biological samples such as cell lysate and plasma using liquid ...

2019-09-16 16:01 1884

Patient Priorities Should be Paramount when Measuring Quality in Cancer Care According to Panelists at NCCN Policy Summit

National Comprehensive Cancer Network hosts summit on defining, measuring, and applying quality in an evolving health policy landscape and the implications for cancer care.#NCCNPolicy WASHINGTON, Sept. 13, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) hosted a policy su...

2019-09-13 01:30 2641

Traditional Chinese Medicine Giant DEEJ Partners with 111 for Direct Sourcing

SHANGHAI, Sept. 12, 2019 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, today announced the signing of a strategic cooperation agreement with Dong-E-E-Jiao Co., Ltd. ("DEEJ") (SZ: 000423), a leading company principally...

2019-09-12 23:16 7658
1 ... 282283284285286287288 ... 295